Focal Interest
Focal Interest
AI Summary of Peer-Reviewed Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Publishing process signals: MODERATE — reflects the venue and review process. — venue and review process.

Turkish drug recalls were driven by contamination, sterility, and safety issues

A grid display of multiple pharmaceutical tablets and capsules in various colors arranged in organized rows against a blue background, showing different medication forms used in quality control inspection.
Research area:MedicinePublic Health, Environmental and Occupational HealthPharmaceutical industry and healthcare

What the study found

TITCK drug recall reports from 2018 to 2024 covered 133 different brands from 67 pharmaceutical companies. The study found that 14 reasons were involved in recalls, and the most common recall levels were 1st Class A and 1st Class B.

What the authors say this matters
The authors conclude that focusing on the reasons behind recalls may reduce the number of recalls. They also suggest that regular drug recall reporting by TITCK Scientific Committees could minimize possible safety-related errors.

What the researchers tested

The researchers carried out a retrospective analysis of drug recalls posted on the TITCK website between 2018 and 2024. They systematically listed recall data and analyzed them by year for the number of drugs and the level of recall.

What worked and what didn't

The most notable recall reasons included contamination, particles, foreign bodies, sterility, European Medicines Agency (EMA) warnings, Food and Drug Administration (FDA) warnings, packaging incompatibility, safety problems, TITCK Scientific Committees, and voluntary recall requests by licensed companies. The highest number of recalls was in 2021, with 30 companies and 44 drugs.

What to keep in mind

The abstract does not describe detailed limitations beyond the retrospective design and the fact that the analysis was based on TITCK website reports. It also does not provide additional data on the causes behind each recall beyond the listed reasons.

Key points

  • Between 2018 and 2024, TITCK recall reports covered 133 brands from 67 pharmaceutical companies.
  • Fourteen recall reasons were identified, including contamination, sterility, and safety problems.
  • The most common recall levels were 1st Class A and 1st Class B.
  • The most recalls occurred in 2021, when 30 companies and 44 drugs were involved.
  • The authors suggest that attention to recall reasons and regular reporting by TITCK Scientific Committees may reduce safety-related errors.

Disclosure

Research title:
Turkish drug recalls were driven by contamination, sterility, and safety issues
Publication date:
2026-02-28
DOI:
10.53424/balikesirsbd.1712550
OpenAlex record:
View
AI provenance: AI provenance information is not available for this post.

More posts